問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

Study Statistics

5576Cases

20022027

Total

5576

  • I

    615

  • I/II

    269

  • II

    1305

  • II/III

    138

  • III

    2775

  • IV

    109

  • Others

    363

Principal Investigator

2781Doctors

Co-Principal Investigator

8684Doctors

Hospital

123Sites

List

5576Cases

2022-09-01 - 2025-12-31

Phase I

Active
A Phase 1 First in Human Study Evaluating Safety, Pharmacokinetics and Efficacy of ABBV-400 as Monotherapy and in Combination With Bevacizumab in Adult Subjects With Advanced Solid Tumors

  • Condition/Disease

    Advanced Solid Tumors

  • Test Drug

    ABBV-400

Participate Sites
11Sites

Not yet recruiting3Sites

Recruiting8Sites

2025-04-01 - 2029-11-30

Phase I

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Recruiting2Sites

2023-12-01 - 2026-07-11

Phase I

Active

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2014-03-20 - 2018-03-20

Phase III

Completed
A Phase 3 Randomized, Placebo-Controlled Trial of Carboplatin and Paclitaxel With or Without the PARP Inhibitor Veliparib (ABT-888) in HER2 Negative Metastatic or Locally Advanced Unresectable BRCA-Associated

  • Condition/Disease

    BRCA-Associated Breast Cancer

  • Test Drug

    Veliparib

Participate Sites
2Sites

Terminated2Sites

2016-04-01 - 2020-11-30

Phase III

Completed
A Phase 3, Randomized, Double-Blind Study Comparing ABT-494 Once Daily Monotherapy to Methotrexate (MTX) Monotherapy in MTX-Naïve Subjects with Moderately to Severely Active Rheumatoid Arthritis

  • Condition/Disease

    Moderately to Severely Active Rheumatoid Arthritis

  • Test Drug

    ABT-494

Participate Sites
4Sites

Terminated3Sites

藍忠亮
China Medical University Hospital-Taipei

未分科

聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB